SiTime Corporation (SITM) Stock Price Today
Aura AI Summary
Key Stats
- $14.20BMarket Cap
- 628,600Volume
- TechnologySector
- $901.6052W High
- $252.7652W Low
- 18 DaysTypical Hold Time
- $13.60BEnterprise Value
- -Div Yield
- -Trading Activity
Track SiTime Corporation (SITM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, SiTime Corporation has traded between a low of $252.76 and a high of $901.6, highlighting its annual price range. Buy and sell SiTime Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Most Recent News
Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...

Ekalia partners with Telix to boost astatine-211 production in the US for cancer therapy.
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...

Roche unveils pivotal cancer drug data at ESMO 2026, highlighting advances in lung and breast cancer treatments.
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.